Drug Search Results
More Filters [+]

Ozanezumab

Alternative Names: ozanezumab, gsk1223249
Latest Update: 2024-04-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NOGO Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ozanezumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Amyotrophic Lateral Sclerosis

Phase 1: Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Amyotrophic Lateral Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

N/A

Not yet recruiting

Breast Cancer

2019-12-31

Ozanezumab Phase II study in patients with ALS

P2

Completed

Amyotrophic Lateral Sclerosis

2015-06-06

NCT01753076

P2

Completed

Amyotrophic Lateral Sclerosis

2015-01-22

NCT01435993

P1

Terminated

Multiple Sclerosis, Relapsing-Remitting

2012-01-23

22%

Recent News Events